Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Vortex Biosciences Announces Publication in Prenatal Diagnosis journal using its technology for enrichment of circulating trophoblasts from maternal blood liquid biopsy

The peer-reviewed publication demonstrates the versatility and flexibility of applications of the Vortex VTX-1 platform. Working in partnership with the team of Prof. Filip Van Nieuwerburgh, at Ghent University in Belgium, this publication describes the use of Vortex's technology to enrich circulating trophoblasts (CTs) from a single tube of maternal blood at week 11-13 of gestation. This is a significant demonstration of the label-free isolation of CTs from maternal blood with the VTX-1 platform.


News provided by

Vortex Biosciences

Mar 08, 2021, 05:00 ET

Share this article

Share toX

Share this article

Share toX


PLEASANTON, Calif., March 8, 2021 /PRNewswire-PRWeb/ -- Vortex Biosciences, provider of circulating tumor cell (CTC) capture systems, today announced the publication of "Enrichment of circulating trophoblasts from maternal blood using laminar microscale vortices" in Prenatal Diagnosis on January 12, 2021.

The peer-reviewed publication describes the use of the Vortex technology to enrich circulating trophoblasts (CTs) from a single tube of maternal blood at week 11-13 of gestation.

This path-breaking research illustrates the growing number of use cases for Vortex’ market-leading cell-isolation technology, not only in the cancer research space but in other important areas such as prenatal research.

Post this

The research was completed by the team of Prof. Filip Van Nieuwerburgh at Ghent University in Belgium. Study co-authors include Dr. Ann-Sophie Vander Plaetsen and doctoral fellow Jana Weymaere.

Prenatal genomic-based testing is now an option for expecting parents to make informed decisions on their pregnancy, as well as to consider preemptive actions regarding the health of their neonate. Clinical implementation of cell-free non-invasive prenatal testing (cfNIPT) is expanding worldwide and has led to a reduction of invasive and risky procedures such as amniocentesis. However, mostly, this technology only detects larger genetic aberrations such as aneuploidies. Cell-based non-invasive prenatal testing (cbNIPT) is a promising alternative that focuses on the CT isolation from maternal blood to enable the genetic analysis of the entire fetal genome.

In this study, a combined workflow was developed and characterized for CT isolation from maternal blood. VTX-1 performance evaluation in spike-in experiments with trophoblasts cell lines resulted in a recovery of +/- 35%. Recovery of CTs was then confirmed for 7/10 first-trimester samples from pregnant women carrying a male fetus. Using a Y-chromosome specific qPCR assay, between 2 and 6 CTs were detected from 8 mL of maternal blood.

Dr. Corinne Renier, Director of R&D of Vortex Biosciences, commented, "This is a first demonstration of the label-free isolation of CTs from maternal blood with the VTX-1, and a first step towards cell-based NIPT. This study also illustrates the flexibility and range of our technology and its applicability to other blood circulating rare cells that may prove valuable for personalized medicine".

"VTX-1 allows size-based enrichment of CTs starting from whole blood without pre-enrichment. Moreover, the enriched cells are of high purity, which facilitates downstream staining, selection, and isolation of single CTs", said Prof. Van Nieuwerburgh, Professor at Ghent University. "Our goal is to implement the VTX-1 enrichment in a beginning-to-end cbNIPT workflow".

"This path-breaking research illustrates the growing number of use cases for Vortex's market-leading cell-isolation technology, not only in the cancer research space but in other important areas such as prenatal research. We look forward to further growth in adoption of Vortex's RUO platform in these growing markets". Dr. Ilian Iliev, Executive Chairman of Vortex.

About Vortex Biosciences

Vortex Biosciences provides an automated, label-free, benchtop solution for isolation and purification of Circulating Tumor Cells (CTCs) from a standard 8 ml tube of blood. The VTX-1 instrument rapidly processes the sample through micro vortices to enrich the CTCs and delivers these highly purified cells into a choice of collection formats. These samples containing viable, undamaged CTCs are easily integrated into downstream genomics, protein markers testing, single cell analysis and staining techniques. Vortex Biosciences is backed by EMV Capital, a subsidiary of NetScientific PLC, and other private investors.

About Ghent University – Laboratory of Pharmaceutical Biotechnology

Ghent University is a top 100 university and one of the major universities in Belgium. Its 11 faculties offer more than 200 courses and conduct in-depth research within a wide range of scientific domains. The team of Prof. Van Nieuwerburgh is focused on topics making use of the many applications of massively parallel sequencing, including bioinformatics. They have the expertise to perform single cell genome-wide (epi)genomics and transcriptomics. Going after the elusive fetal cells in maternal blood is a logical next step and a current focus. Non-invasive access to fetal cells during pregnancies would revolutionize the field of prenatal testing.

For further information regarding the Vortex VTX-1 platform or possible trial of the instrument please contact [email protected].

Media Contact

Chris Howie, Vortex Biosciences, +1 (650) 252-2262, [email protected]

SOURCE Vortex Biosciences

Related Links

https://vortexbiosciences.com

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.